Affiliations 

  • 1 Department of Molecular and Translational Science, Monash University, Clayton 3168, Australia
  • 2 Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Kuala Lumpur 57000, Malaysia
  • 3 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney 2007, Australia
  • 4 School of Pharmacy and Pharmacology, University of Tasmania, Hobart 7005, Australia
  • 5 Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida 201310, UP, India
  • 6 School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston 7248, Australia
  • 7 School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine BT52 1SA, UK
Viruses, 2021 Jul 18;13(7).
PMID: 34372603 DOI: 10.3390/v13071397

Abstract

The recent coronavirus disease 2019 (COVID-19) outbreak has drawn global attention, affecting millions, disrupting economies and healthcare modalities. With its high infection rate, COVID-19 has caused a colossal health crisis worldwide. While information on the comprehensive nature of this infectious agent, SARS-CoV-2, still remains obscure, ongoing genomic studies have been successful in identifying its genomic sequence and the presenting antigen. These may serve as promising, potential therapeutic targets in the effective management of COVID-19. In an attempt to establish herd immunity, massive efforts have been directed and driven toward developing vaccines against the SARS-CoV-2 pathogen. This review, in this direction, is aimed at providing the current scenario and future perspectives in the development of vaccines against SARS-CoV-2.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.